Searching for a successful HDL-based treatment strategy

Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

Volumn 1841, Issue 1, 2014, Pages 162-167

  Reddy, Srinivasa T ^a   Navab, Mohamad ^a   Anantharamaiah, G M ^b   Fogelman, Alan M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b and Clinical Center   (United States)

Author keywords

Apolipoprotein A I; Apolipoprotein A I mimetic peptide 6F; Atherosclerosis; Cancer; HDL; Lysophosphatidic acid

Indexed keywords

AMINO ACID; ASPARTYLTRYPTOPHYLLEUCYLALANYLTYROSYLASPARTYLLYSYLPHENYLALANYLPHENYLALANYLGLUTAMYLLYSYLPHENYLALANYLLYSYLGLUTAMYLPHENYLALANYLPHENYLALANINE AMIDE; ASPARTYLTRYPTOPHYLLEUCYLLYSYLALANYLPHENYLALANYLTYROSYLASPARTYLLYSYLLYSYLVALYLPHENYLALANYLGLUTAMYLPHENYLALANYLPHENYLALANINE AMIDE; ASPARTYLTRYPTOPHYLLEUCYLLYSYLALANYLPHENYLALANYLTYROSYLASPARTYLLYSYLPHENYLALANYLPHENYLALANYLGLUTAMYLLYSYLPHENYLALANYLLYSYLGLUTAMYLPHENYLALANYLPHENYLALANINE; ASPARTYLTRYTOPHYLLEUCYLLYSYLALANYLTYROSYLASPARTYLLYSYLVALYLALANYLGLUTAMYLLYSYLLEUCYLLYSYLGLUTAMYLALANYLPHENALALANINE AMIDE; ASPARTYLTRYTOPHYLPHENYLALANYLLYSYLALANYLPHYENYLALANYLTYROSYLASPARTYLLYSYLPHENYLALANYLPHENYLALANYLGLUTAMYLLYSYSLPHENYLALANYLLYSYLGLUTAMYLPHENYLALANYLPHENYLALANINE AMIDE; ASPARTYLTRYTOPHYLPHENYLALANYLTYROSYLASPARTYLLYSYLVALYLALANYLGLUTAMYLLYSYLPHENYLALALNYLLYSYLGLUTAMYLALANYLPHEYNYLALANINE AMIDE; FIBROBLAST GROWTH FACTOR RECEPTOR 1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LYSOPHOSPHATIDIC ACID; PEPTIDE DERIVATIVE; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ARTICLE; ATHEROSCLEROSIS; CANCER INHIBITION; CANCER THERAPY; CHRONIC INFLAMMATION; DRUG EFFICACY; HUMAN; INTESTINE; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 84887284180     PISSN: 13881981     EISSN: 18792618     Source Type: Journal    
DOI: 10.1016/j.bbalip.2013.10.012     Document Type: Review

References (52)

1. T. Gordon, W.P. Castelli, M.C. Hjortland, W.B. Kannel, and T.R. Dawber High density lipoprotein as a protective factor against coronary heart disease. The Framingham study Am. J. Med. 62 1977 707 714 (Pubitemid 8110784)
2. P. Linsel-Nitschke, and A.R. Tall HDL as a target in the treatment of atherosclerotic cardiovascular disease Nat. Rev. Drug Discov. 4 2005 193 205 (Pubitemid 40372554)
3. H.N. Ginsberg, M.B. Elam, L.C. Lovato, J.R. Crouse, L.A. Leiter, P. Linz, W.T. Friedewald, J.B. Buse, H.C. Gerstein, J. Probstfield, R.H. Grimm, F. Ismail-Beigi, J.T. Bigger, D.C. Goff Jr., W.C. Cushman, D.G. Simons-Morton, and R.P. Byington Effects of combination lipid therapy in type 2 diabetes mellitus N. Engl. J. Med. 362 2010 1563 1574
4. P.J. Barter, M. Caulfield, M. Eriksson, S.M. Grundy, J.J. Kastelein, M. Komajda, J. Lopez-Sendon, L. Mosca, J.C. Tardif, D.D. Waters, C.L. Shear, J.H. Revkin, K.A. Buhr, M.R. Fisher, A.R. Tall, B. Brewer, and ILLUMINATE Investigators Effects of torcetrapib in patients at high risk for coronary events N. Engl. J. Med. 357 2007 2109 2122 (Pubitemid 350146106)
5. AIM-HIGH Investigators, W.E. Boden, J.L. Probstfield, T. Anderson, B.R. Chaitman, P. Desvignes-Nickens, K. Koprowicz, R. McBride, K. Teo, and W. Weintraub Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy N. Engl. J. Med. 365 2011 2255 2267
6. G.G. Schwartz, A.G. Olsson, M. Abt, C.M. Ballantyne, P.J. Barter, J. Brumm, B.R. Chaitman, I.M. Holme, D. Kallend, L.A. Leiter, E. Leitersdorf, J.J. McMurray, H. Mundl, S.J. Nicholls, P.K. Shah, J.C. Tardif, and R.S. Wright Effects of dalcetrapib in patients with a recent acute coronary syndrome N. Engl. J. Med. 367 2012 2089 2099
7. B.F. Voight, G.M. Peloso, M. Orho-Melander, R. Frikke-Schmidt, M. Barbalic, M.K. Jensen, G. Hindy, H. Holm, E.L. Ding, T. Johnson, H. Schunkert, N.J. Samani, R. Clarke, J.C. Hopewell, J.F. Thompson, M. Li, G. Thorleifsson, C. Newton-Cheh, K. Musunuru, J.P. Pirruccello, D. Saleheen, L. Chen, A. Stewart, A. Schillert, U. Thorsteinsdottir, G. Thorgeirsson, S. Anand, J.C. Engert, T. Morgan, J. Spertus, M. Stoll, K. Berger, N. Martinelli, D. Girelli, P.P. McKeown, C.C. Patterson, S.E. Epstein, J. Devaney, M.S. Burnett, V. Mooser, S. Ripatti, I. Surakka, M.S. Nieminen, J. Sinisalo, M.L. Lokki, M. Perola, A. Havulinna, U. de Faire, B. Gigante, E. Ingelsson, T. Zeller, P. Wild, P.I. de Bakker, O.H. Klungel, A.H. Maitland-van der Zee, B.J. Peters, A. de Boer, D.E. Grobbee, P.W. Kamphuisen, V.H. Deneer, C.C. Elbers, N.C. Onland-Moret, M.H. Hofker, C. Wijmenga, W.M. Verschuren, J.M. Boer, Y.T. van der Schouw, A. Rasheed, P. Frossard, S. Demissie, C. Willer, R. Do, J.M. Ordovas, G.R. Abecasis, M. Boehnke, K.L. Mohlke, M.J. Daly, C. Guiducci, N.P. Burtt, A. Surti, E. Gonzalez, S. Purcell, S. Gabriel, J. Marrugat, J. Peden, J. Erdmann, P. Diemert, C. Willenborg, I.R. Konig, M. Fischer, C. Hengstenberg, A. Ziegler, I. Buysschaert, D. Lambrechts, F. Van de Werf, K.A. Fox, N.E. El Mokhtari, D. Rubin, J. Schrezenmeir, S. Schreiber, A. Schafer, J. Danesh, S. Blankenberg, R. Roberts, R. McPherson, H. Watkins, A.S. Hall, K. Overvad, E. Rimm, E. Boerwinkle, A. Tybjaerg-Hansen, L.A. Cupples, M.P. Reilly, O. Melander, P.M. Mannucci, D. Ardissino, D. Siscovick, R. Elosua, K. Stefansson, C.J. O'Donnell, V. Salomaa, D.J. Rader, L. Peltonen, S.M. Schwartz, D. Altshuler, and S. Kathiresan Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study Lancet 380 2012 572 580
8. A. von Eckardstein Implications of torcetrapib failure for the future of HDL therapy: is HDL-cholesterol the right target? Expert. Rev. Cardiovasc. Ther. 8 2010 345 358
9. C. Besler, T.F. Luscher, and U. Landmesser Molecular mechanisms of vascular effects of high-density lipoprotein: alterations in cardiovascular disease EMBO Mol. Med. 4 2012 251 268
10. M. Navab, S.T. Reddy, B.J. Van Lenten, and A.M. Fogelman HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms Nat. Rev. Cardiol. 8 2011 222 232
11. M. Navab, S.T. Reddy, B.J. Van Lenten, G.M. Buga, G. Houg, A.C. Wagner, and A.M. Fogelman High-density lipoprotein and 4F peptide reduce systemic inflammation by modulating intestinal oxidized lipid metabolism: novel hypotheses and review of literature Arterioscler. Thromb. Vasc. Biol. 32 2012 2553 2560
12. M.G. Damiano, R. Kannan Mutharasan, S. Tripathy, K.M. McMahon, and C.S. Thaxton Templated high density lipoprotein nanoparticles as potential therapies and for molecular delivery Adv. Drug Deliv. Rev. 65 2013 649 662
13. G.M. Anantharamaiah, J.L. Jones, C.G. Brouillette, C.F. Schmidt, B.H. Chung, T.A. Hughes, A.S. Brown, and J.P. Segrest Studies of synthetic peptide analogs of amphipathic helix I: structure of peptide/DMPC complexes J. Biol. Chem. 260 1985 10248 10255 (Pubitemid 16246560)
14. G.M. Anantharamiah Synthetic peptide analogs of apolipoproteins Methods Enzymol. 128 1986 627 647
15. G. Datta, M. Chaddha, S. Hama, M. Navab, A.M. Fogelman, D.W. Garber, V.K. Mishra, R.M. Epand, R.F. Epand, S. Lund-Katz, M.C. Phillips, J.P. Segrest, and G.M. Anantharamaiah Effects of increasing hydrophobicity on the physical-chemical and biological properties of a class A amphipathic helical peptide J. Lipid Res. 42 2001 1096 1104 (Pubitemid 32645791)
16. D.W. Garber, G. Datta, M. Chaddha, M.N. Palgunachari, S.Y. Hama, M. Navab, A.M. Fogelman, J.P. Segrest, and G.M. Anantharamiah A new synthetic class A amphipathic peptide analogue protects mice from diet-induced atherosclerosis J. Lipid Res. 42 2001 545 552 (Pubitemid 32366997)
17. M. Navab, I. Shechter, G.M. Anantharamaiah, S.T. Reddy, B.J. Van Lenten, and A.M. Fogelman Structure and function of HDL mimetics Arterioscler. Thromb. Vasc. Biol. 30 2010 164 168
18. G.S. Getz, and C.A. Reardon Apolipoprotein A-I and A-I mimetic peptides: a role in atherosclerosis J. Inflamm. Res. 4 2011 83 92
19. B.J. Van Lenten, A.C. Wagner, C.L. Jung, P. Ruchala, A.J. Waring, R.I. Lehrer, A.D. Watson, S. Hama, M. Navab, G.M. Anantharamaiah, and A.M. Fogelman Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-I J. Lipid Res. 49 2008 2302 2311
20. B.J. Van Lenten, A.C. Wagner, M. Navab, G.M. Anantharamaiah, S. Hama, S.T. Reddy, and A.M. Fogelman Lipoprotein inflammatory properties and serum amyloid A levels but not cholesterol levels predict lesion area in cholesterol-fed rabbits J. Lipid Res. 48 2007 2344 2353 (Pubitemid 350058746)
21. G.M. Anantharamaiah, V.K. Mishra, D.W. Garber, G. Datta, S.P. Handattu, M.N. Palgunachari, M. Chddha, M. Reddy, S.T. Reddy, J.P. Segrest, and A.M. Fogelman Structural requirements for antioxidative and anti-inflammatory properties of apolipoprotein A-I mimetic peptides J. Lipid Res. 48 2007 1915 1923 (Pubitemid 47360611)
22. K.R. Kozak, M.W. Amneus, S.M. Pusey, F. Su, M.N. Luong, S.A. Luong, S.T. Reddy, and R. Farias-Eisner Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: potential use in diagnosis and prognosis Proc. Natl. Acad. Sci. U. S. A. 100 2003 12343 12348 (Pubitemid 37271562)
23. K.R. Kozak, F. Su, J.P. Whitelegge, K. Faull, S. Reddy, and R. Farias-Eisner Characterization of serum biomarkers for detection of early stage ovarian cancer Proteomics 5 2005 4589 4596 (Pubitemid 41739936)
24. V. Nossov, M. Amneus, F. Su, J. Lang, J.M. Janco, S.T. Reddy, and R. Farias-Eisner The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125? Am. J. Obstet. Gynecol. 199 2008 215 223
25. V. Nossov, F. Su, M. Amneus, M. Birrer, T. Robbins, J. Kotlerman, S. Reddy, and R. Farias-Eisner Validation of serum biomarkers for detection of early-stage ovarian cancer Am. J. Obstet. Gynecol. 200 2009 639.e1-5
26. Y. Xu, Z. Shen, D.W. Wiper, M. Wu, R.E. Morton, P. Elson, A.W. Kennedy, J. Belinson, M. Markman, and G. Casey Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers JAMA 280 1998 719 723 (Pubitemid 28405297)
27. G.B. Mills, and W.H. Moolenaar The emerging role of lysophosphatidic acid in cancer Nat. Rev. Cancer 3 2003 582 591 (Pubitemid 37328830)
28. R. Sutphen, Y. Xu, G.D. Wilbanks, J. Fioica, E.C. Grendys Jr., J.P. LaPolla, H. Arango, M.S. Hoffman, M. Martino, K. Wakeley, D. Griffin, R.W. Blanco, A.B. Cantor, Y.J. Xiao, and J.P. Krischer Lysophospholipids are potential biomarkers of ovarian cancer Cancer Epidemiol. Biomarkers Prev. 13 2004 1185 1191 (Pubitemid 38917907)
29. H. Li, D. Wang, H. Zhang, K. Kirmani, Z. Zhao, R. Steinmetz, and Y. Xu Lysophosphatidic acid stimulates cell migration, invasion and colony formation as well as tumorigenesis/metastasis of mouse ovarian cancer in immunocompetent mice Mol. Cancer Ther. 8 2009 1692 1701
30. F. Su, K.R. Kozak, S. Imaizumi, F. Gao, M.W. Amneus, V. Grijalva, C. Ng, A. Wagner, G. Hough, G. Farias-Eisner, G.M. Anantharamaiah, B.J. Van Lenten, M. Navab, A.M. Fogelman, S.T. Reddy, and R. Farias-Eisner Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer PNAS 107 2010 19997 20002
31. K.F. Roby, C.C. Taylor, J.P. Sweetwood, Y. Cheng, J.L. Pace, O. Tawfik, D.L. Person, P.G. Smith, and P.F. Terranova Development of a syngeneic mouse model for events related to ovarian cancer Carcinogenesis 21 2000 585 591 (Pubitemid 30214011)
32. J. Greenaway, J. Henkin, J. Lawler, R. Moorehead, and J. Petrik ABT-510 induces tumor cell apoptosis and inhibits ovarian tumor growth in an orthotopic, syngenic model of epithelial ovarian cancer Mol. Cancer Ther. 8 2009 64 74
33. Y. Pengetnze, M. Steed, K.F. Roby, P.F. Terranova, and C.C. Taylor Src tyrosine kinase promotes survival and resistance to chemotherapeutics in a mouse ovarian cancer cell line Biochem. Biophys. Res. Commun. 309 2003 377 383 (Pubitemid 37025902)
34. F. Gao, S.X. Vasquez, F. Su, S. Roberts, N. Shah, V. Grijalva, S. Imaizumi, A. Chattopadhyay, E. Ganapathy, D. Meriwether, B. Johnston, G.M. Anantharamaiah, M. Navab, A.M. Fogelman, S.T. Reddy, and R. Farias-Eisner L-5F, an apolipoprotein A-I mimetic, inhibits tumor angiogenesis by suppressing VEGF/basic FGF signaling pathways Integr. Biol. 3 2011 479 489
35. E. Ganapathy, F. Su, D. Meriwether, A. Devarajan, V. Grijalva, F. Gao, A. Chattopadhyay, G.M. Anantharamiah, M. Navab, A.M. Fogelman, S.T. Reddy, and R. Farias-Eisner D-4F, an apoA-I mimetic peptide, inhibits proliferation and tumorigenicity of epithelial ovarian cancer cells by upregulating the antioxidant enzyme MnSOD Int. J. Cancer 130 2012 1071 1081
36. A.E. Cust, R. Kaaks, C. Friedenreich, F. Bonnet, M. Laville, A. Tjonneland, A. Olsen, K. Overvad, M.U. Jakobsen, V. Chajes, F. Clavel-Chapelon, M.C. Boutron-Ruault, J. Linseisen, A. Lukanova, H. Boeing, T. Pischon, A. Trichopoulou, B. Christina, D. Trichopoulos, D. Palli, F. Berrino, S. Pnico, R. Tumino, C. Sacerdote, I.T. Gram, E. Lund, J.R. Quiros, N. Travier, C. Martinez-Garcia, N. Larranga, M.D. Chiriaque, E. Ardanaz, G. Berglund, E. Lundin, H.B. Bueno-de-Mesquita, F.J. van Duijnhoven, P.H. Peeters, S. Bingham, K.T. Khaw, N. Allen, T. Key, P. Ferrari, S. Rinaldi, N. Slimani, and E. Riboli Metabolic syndrome, plasma lipid, lipoprotein and glucose levels, and endometrial cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) Endocr. Relat. Cancer 14 2007 755 767 (Pubitemid 350074064)
37. F.J. van Duijnhoven, H.B. Bueno-De-Mesquita, M. Calligaro, M. Jenab, T. Pischon, E.H. Jansen, J. Frohlich, A. Ayyobi, K. Overvad, A.P. Toft-Petersen, A. Tjonneland, L. Hansen, M.C. Boutron-Ruault, F. Clavel-Chapelon, V. Cottet, D. Palli, G. Tagliabue, S. Panico, R. Tumino, P. Vineis, R. Kaaks, B. Teucher, H. Boeing, D. Drogan, A. Trichopoulou, P. Lagiou, V. Dilis, P.H. Peeters, P.D. Siersema, L. Rodriguez, C.A. Gonzalez, E. Molina-Montes, M. Dorronsoro, M.J. Tormo, A. Barricarte, R. Palmqvist, G. Hallmans, K.T. Khaw, K.K. Tsilidis, F.L. Crowe, V. Chajes, V. Fedirko, S. Rinaldi, T. Norat, and E. Riboli Blood lipid and lipoprotein concentrations and colorectal cancer risk in the European Prospective Investigation into Cancer and Nutrition Gut 60 2011 1094 1102
38. F. Su, V. Grijalva, K. Navab, E. Ganapathy, D. Meriwether, S. Imaizumi, M. Navab, A.M. Fogelman, S.T. Reddy, and R. Farias-Eisner HDL mimetics inhibit tumor development in both induced and spontaneous mouse models of colon cancer Mol. Cancer Ther. 11 2012 1311 1319
39. F. Gao, A. Chattopadhyay, M. Navab, V. Grijalva, F. Su, A.M. Fogelman, S.T. Reddy, and R. Farias-Eisner Apolipoprotein A-I mimetic peptides inhibit expression and activity of hypoxia-inducible factor 1-a in human ovarian cancer cell lines and a mouse ovarian cancer model J. Pharmacol. Exp. Ther. 342 2012 255 262
40. A. Mantovani, P. Allavena, A. Sica, and F. Balkwill Cancer-related inflammation Nature 454 2008 436 444
41. B.-Z. Qian, and J.W. Pollard Macrophage diversity enhances tumor progression and metastasis Cell 141 2010 39 51
42. C. Neyen, A. Pluddemann, S. Mukhopadhyay, E. Maniati, M. Bossard, S. Gordon, and T. Hagemann Macrophage scavenger receptor A promotes tumor progression in murine models of ovarian and pancreatic cancer J. Immunol. 190 2013 3798 3805
43. C. Neyen, A. Pluddemann, P. Roversi, B. Thomas, L. Cai, D.R. van der Westhuyzen, R.B. Sim, and Siamon Gordon Macrophage scavenger receptor A mediates adhesion to apolipoproteins A-I and E Biochemistry 48 2009 11858 11871
44. C. Neyen, S. Mukhopadhyay, S. Gordon, and T. Hagemann An apolipoprotein A-I mimetic targets scavenger receptor A on tumor-associated macrophages. A prospective treatment? Oncoimmunology 2 2013 e24461
45. C.-L. Chang, H.-Y. Hsu, H.-Y. Lin, W. Chiang, and H. Lee Lysophosphatidic acid-induced oxidized low-density lipoprotein uptake is class A scavenger receptor-dependent in macrophages Prostaglandins Other Lipid Mediat. 87 2008 20 25
46. L.T. Bloedon, R. Dunbar, D. Duffy, P. Pinell-Salles, R. Norris, B.J. DeGroot, R. Movva, M. Navab, A.M. Fogelman, and D.J. Rader Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients J. Lipid Res. 49 2008 1344 1352
47. C.E. Watson, N. Weissbach, L. Kjems, S. Ayalasomayajula, Y. Zhang, I. Chang, M. Navab, S. Hama, G. Hough, S.T. Reddy, D. Soffer, D.J. Rader, A.M. Fogelman, and A. Schecter Treatment of patients with cardiovascular disease with L-4F, an apo-A1 mimetic, did not improve select biomarkers of HDL function J. Lipid Res. 52 2011 361 373
48. M. Navab, S.T. Reddy, G.M. Anantharamaiah, S. Imaizumi, G. Hough, S. Hama, and A.M. Fogelman Intestine may be a major site of action for the apoA-I mimetic peptide 4F whether administered subcutaneously or orally J. Lipid Res. 52 2011 1200 1210
49. M. Navab, S.T. Reddy, G.M. Anantharamaiah, G. Hough, G.M. Buga, J. Danciger, and A.M. Fogelman D-4F-mediated reduction in metabolites of arachidonic and linoleic acids in the small intestine is associated with decreased inflammation in low-density lipoprotein receptor-null mice J. Lipid Res. 53 2012 437 445
50. G.S. Getz, and C.A. Reardon Apoa-I mimetics: tomatoes to the rescue J. Lipid Res. 54 2013 878 880
51. A. Chattopadhyay, M. Navab, G. Hough, F. Gao, D. Meriwether, V. Grijalva, J.R. Springstead, M.N. Palgnachari, R. Namiri-Kalantari, F. Su, B.J. Van Lenten, A.C. Wagner, G.M. Anantharamaiah, R. Farias-Eisener, S.T. Reddy, and A.M. Fogelman A novel approach to oral apoA-I mimetic therapy J. Lipid Res. 54 2013 995 1010
52. M. Navab, G. Hough, G.M. Buga, F. Su, A.C. Wagner, D. Meriwether, A. Chattopadhyay, F. Gao, V. Grijalva, J.S. Danciger, B. Van Lenten, E. Org, A.J. Lusis, C. Pan, G.M. Anantharamaiah, R. Farias-Eisner, S.S. Smyth, S.T. Reddy, and A.M. Fogelman Transgenic 6F tomatoes act on the small intestine to prevent systemic inflammation and dyslipidemia caused by Western diet and intestinally derived lysophosphatidic acid J. Lipid Res. 2013 (Epub ahead of print)